March 2013
First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals’ Lead Therapeutic Candidate for Treatment of Migraine, ALD403

May 2012
Alder Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403

April 2012
Alder Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics

February 2012
Alder to Participate in Antibody Therapeutics Panel at RBC Capital Market Global Healthcare Conference

November 2010
Alder to Present Data from Multiple Studies of ALD518 at Annual Meeting of the American College of Rheumatology

November 2010
Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors

September 2010
FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15

June 2010
New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

June 2010
Alder Biopharmaceuticals to Present at Two Upcoming Investor Conferences

June 2010
Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients

December 2009
Phase 1 Data on Alder Biopharmaceuticals’ ALD518 to be Presented at 5th Cachexia Conference

November 2009
Alder Biopharmaceuticals to Present at Piper Jaffray & Co. 21st Annual Healthcare Conference

November 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

August 2009
Alder Biopharmaceuticals Appoints Dr. Mark D. Young Senior VP Pharmaceutical Operations

June 2009
Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough

June 2009
Alder Presents Results from Phase I Trial of ALD518 in Advanced Cancer at ASCO Annual Meeting

January 2008
Alder Biopharmaceuticals Inc. Completes $40M Series C Financing

July 2006
Alder Biopharmaceuticals Inc. Completes Series B Financing

March 2006
Alder Biopharmaceuticals Appoints Clay B. Siegall, Ph.D. to Board

December 2005
Alder Biopharmaceuticals Inc. Forms Collaboration with Schering-Plough to Identify and Manufacture Antibody Therapeutics

November 2005
Alder Biopharmaceuticals Inc. Forms Research Collaboration with Seattle Genetics for Production of Antibodies

August 2005
Alder Biopharmaceuticals Inc. Raises $11.1M in Series A Financing

April 2004
Jeffrey T. L. Smith, M.D., Joins Alder Biopharmaceuticals Management Team